CDEK
← All organizations

Iovance

For profitContributed to NMEWebsite ↗

Also known as: Iovance Biotherapeutics | Iovance Biotherapeutics, Inc. | Lion Biotechnologies | Lion Biotechnologies, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 3

First clinical trial

Oct 3, 2012

First marketed drug

Feb 16, 2024

First NDA

Feb 16, 2024

Last known activity

Jan 31, 2026

Timeline

2000s

  1. Jun 1, 2007

    Iovance— Founded

2010s

  1. Oct 31, 2013

    Genesis Biopharma— Acquired

2020s

  1. Feb 16, 2024

    lifileucel— NDA Organization

Drugs by trial phase (19 distinct, 28 trials)

Phase 3 (1 own, 0 via acquisition)

Other trials (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (40)

Details

Founded
New York, NY, US Jun 1, 2007
First NDA
Feb 16, 2024
Last known activity
Jan 31, 2026

Designations held

  • Orphan drug
  • Accelerated approval